Quidelortho Corp. (QDEL) fundamentals score
Its vision is to advance diagnostics to power a healthier future. With its expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, Quidelortho aims to support clarity for clinicians and patients to help create better health outcomes.
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NASDAQ
Overall: 3.8 out of 10, Weak long-term fundamentals
- Growth: 4.0/10
- Profitability: 1.1/10
- Financial health: 2.5/10
- Earnings quality: 9.4/10
- Valuation: 4.3/10
Scores are calculated from Quidelortho Corp.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10